Onc Now: Trials, Translation, and the Future of Uro-Oncology

In this episode, Rob Jones, Professor and Honorary Consultant in Medical Oncology at the University of Glasgow, UK,  joins us to discuss his journey into oncology, the future of the specialty, and the evolving treatment landscape for genitourinary cancers. From clinical trial design and emerging therapies to European Society for Medical Oncology (ESMO) 2025 takeaways and thoughts on prostate cancer screening, Jones shares practical insights drawn from both research and frontline clinical practice.  Timestamps:     00:00 – Introduction  00:43 – Rob's journey into oncology  04:11 – The next generation of oncologists  08:16 – Clinical trial work  10:20 – Intersection of oncology and nephrology  14:05 – Cardiovascular toxicity  19:25 – European Society for Medical Oncology (ESMO) 2025 bladder cancer takeaways  23:53 – Challenges in designing trials  26:35 – Emerging treatment strategies  30:18 – Prostate cancer screening  34:00 – Magic wishes for healthcare    Disclosure: Jones has received research grants from Astellas, Clovis, Exelixis, Bayer, and Roche; advisory board fees from Janssen, Astellas, Bayer, Novartis, Pfizer, Merck Serono, MSD, Roche, Ipsen, and Bristol Myers Squibb; lecture honoraria from Astellas, Janssen, Bayer, Pfizer, Merck Serono, MSD, Roche, Ipsen, and Bristol Myers Squibb; support for conference attendance from Bayer and Janssen; and participated on a Data Safety Monitoring Board or Advisory Board for Roche.